Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
LULUTOX Detox Tea in Consumer Coverage as Website Update Introduces More Transparency in Herbal Digestive Supplement Information
Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support
Profound Medical Corp. Announces Upsize of Private Placement
SAN DIEGO and TOKYO, March 25, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics Inc., a biotechnology company developing next generation...
ORANGE, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”), a mission-based, tech-enabled Medicare...
Provides Business UpdateDALLAS, March 25, 2021 (GLOBE NEWSWIRE) -- Capital Senior Living Corporation (NYSE: CSU) will issue its fourth quarter and full...
BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public...
NOVA LIMA, Brazil and MINAS GERAIS, Brazil, March 25, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA) today...
FORT LAUDERDALE, Fla., March 25, 2021 (GLOBE NEWSWIRE) -- Priveterra Acquisition Corp. (Nasdaq: PMGMU) (the “Company”) today announced that, commencing...
Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results...
IND accepted for VOR33, Vor’s lead eHSC product candidate for treatment of AML Completed initial public offering raising $203.4 million...
Ji’an, Jiangxi, China, March 25, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and...
WATERTOWN, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Since the start of the coronavirus pandemic more than a year ago,...
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced...
Actively recruiting patients in two global, clinical studies evaluating seladelpar in primary biliary cholangitis (PBC): RESPONSE, a 52-week, randomized, placebo-controlled,...
WALTHAM, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company...
MINNEAPOLIS, March 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
NEWTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS DAVID...
Achieved Full Year 2020 Total Revenues of $42.2 Million, a 44% Increase Over Full Year 2019 Accelerated ADMA BioCenters Plasma...
Progressed lead programs VRDN-001 and VRDN-002 towards clinical trials in Thyroid Eye Disease (TED); both IND filings expected by the...
Announces MydCombi expected PDUFA date of October 28, 2021 Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for...
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash...
SAINT-LAURENT, Quebec, March 25, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results...
